Survivin-targeted Strategy For Cancer Treatment | 78137

OMICS Journal of Radiology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences

3rd Global Meeting on Oncology and Radiology

Dubai, UAE
Google scholar citation report
Citations : 363

OMICS Journal of Radiology received 363 citations as per google scholar report

OMICS Journal of Radiology peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Open J Gate
  • Genamics JournalSeek
  • ResearchBible
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
Share This Page

Survivin-targeted strategy for cancer treatment

World Congress on Radiology and Oncology

Ren Chongxi

Hebei Medical University, China

ScientificTracks Abstracts: OMICS J Radiol

DOI: 10.4172/2167-7964-C1-015

Survivin, a new member of inhibitors of apoptosis proteins (IAP) family, regulates the essential cellular processes, including inhibition of cell apoptosis and autophagic cell death, promotion of cell proliferation and tumor stromal angiogenesis. Survivin is undetectable in most terminally differentiated tissues, but upregulated in almost all types of human malignancies and its aberrant overexpression positively correlates with chemotherapy resistance, increased tumor recurrence and shortened patient survival. Because of its key role in tumor formation and development, Survivin is considered as an ideal target for anticancer treatment.This review discussed the molecular function of Survivin, relationship between Survivin and cancer biological characteristics, as well as the research progress of cancer therapy by targeting Survivin.

Ren Chongxi graduated from Hebei Medical University and completed his MD from QingDao University School of Medicine. He is the Director of Department of Surgical Oncology, Hebei Medical University. He has published more than 20 papers in reputed journals and has been serving as an Editorial Board Member of repute.